Opdivo Qvantig

News

BMS beats MSD to the US subcutaneous PD-1 inhibitor market after Opdivo Qvantiq is cleared across nearly all the indications of the IV form.

News

Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.